Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74606 | 1.00 | TAAR1 (0.45) | TAAR1HRH1ADRB2ADRB1CHRM2 | |
| SCHEMBL10056778 | 1.00 | TAAR1 (0.45) | TAAR1HRH1ADRB2ADRB1CHRM2 | |
| SCHEMBL9882960 | 0.87 | TAAR1 (0.47) | TAAR1HRH1ADRB2ADRB1CHRM2 | |
| SCHEMBL74307 | 0.86 | THRA (0.43) | ADRB2ADRB1HTR1AADRA2AADRA2B | |
| SCHEMBL73798 | 0.86 | THRA (0.43) | ADRB2ADRB1HTR1AADRA2AADRA2B | |
| SCHEMBL12090288 | 0.86 | THRA (0.43) | ADRB2ADRB1HTR1AADRA2AADRA2B | |
| SCHEMBL14092096 | 0.84 | THRA (0.49) | ADRB2ADRB1HTR1AADRA2AADRA2B | |
| SCHEMBL8796327 | 0.83 | TAAR1 (0.38) | TAAR1 | |
| SCHEMBL22397181 | 0.83 | TAAR1 (0.38) | TAAR1 | |
| SCHEMBL1470815 | 0.83 | TAAR1 (0.50) | TAAR1HRH1ADRB2ADRB1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | TAAR1 637/4885HRH1 115/4885ADRB2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.